74 related articles for article (PubMed ID: 12122920)
1. Unbinding pathways of an agonist and an antagonist from the 5-HT3 receptor.
Thompson AJ; Chau PL; Chan SL; Lummis SC
Biophys J; 2006 Mar; 90(6):1979-91. PubMed ID: 16387779
[TBL] [Abstract][Full Text] [Related]
2. 5-HT6 receptor antagonists as novel cognitive enhancing agents for Alzheimer's disease.
Upton N; Chuang TT; Hunter AJ; Virley DJ
Neurotherapeutics; 2008 Jul; 5(3):458-69. PubMed ID: 18625457
[TBL] [Abstract][Full Text] [Related]
3. Serotonergic modulating drugs for functional gastrointestinal diseases.
Spiller R
Br J Clin Pharmacol; 2002 Jul; 54(1):11-20. PubMed ID: 12100220
[TBL] [Abstract][Full Text] [Related]
4. The serotonin 5-HT3 receptor: a novel neurodevelopmental target.
Engel M; Smidt MP; van Hooft JA
Front Cell Neurosci; 2013; 7():76. PubMed ID: 23761731
[TBL] [Abstract][Full Text] [Related]
5. Eicosapentaenoic Acid Modulates Transient Receptor Potential V1 Expression in Specific Brain Areas in a Mouse Fibromyalgia Pain Model.
Liao HY; Yen CM; Hsiao IH; Hsu HC; Lin YW
Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474148
[TBL] [Abstract][Full Text] [Related]
6. Anti-stress neuropharmacological mechanisms and targets for addiction treatment: A translational framework.
Greenwald MK
Neurobiol Stress; 2018 Nov; 9():84-104. PubMed ID: 30238023
[TBL] [Abstract][Full Text] [Related]
7. Fibromyalgia: When Distress Becomes (Un)sympathetic Pain.
Martinez-Lavin M
Pain Res Treat; 2012; 2012():981565. PubMed ID: 22110948
[TBL] [Abstract][Full Text] [Related]
8. What is the progress of experimental drug development for fibromyalgia?
Lawson K
Expert Opin Investig Drugs; 2023; 32(7):563-565. PubMed ID: 37357750
[No Abstract] [Full Text] [Related]
9. Specific treatment of residual fatigue in depressed patients.
Marin H; Menza MA
Psychiatry (Edgmont); 2004 Sep; 1(2):12-8. PubMed ID: 21197374
[No Abstract] [Full Text] [Related]
10. [What's new in the therapy of fibromyalgia?].
Späth M
Schmerz; 2003 Dec; 17(6):437-40. PubMed ID: 14648317
[TBL] [Abstract][Full Text] [Related]
11. Management of fibromyalgia.
Patkar AA; Bilal L; Masand PS
Curr Psychiatry Rep; 2003 Jul; 5(3):218-24. PubMed ID: 12773276
[TBL] [Abstract][Full Text] [Related]
12. Do predictors exist for the therapeutic effect of 5-HT3 receptor antagonists in fibromyalgia?
Stratz T; Müller W
Scand J Rheumatol Suppl; 2000; 113():63-5. PubMed ID: 11028835
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and tolerability of tropisetron in primary fibromyalgia--a highly selective and competitive 5-HT3 receptor antagonist. German Fibromyalgia Study Group.
Färber L; Stratz T; Brückle W; Späth M; Pongratz D; Lautenschläger J; Kötter I; Zöller B; Peter HH; Neeck G; Alten R; Müller W
Scand J Rheumatol Suppl; 2000; 113():49-54. PubMed ID: 11028832
[TBL] [Abstract][Full Text] [Related]
14. Preclinical and clinical pharmacology of the 5-HT3 receptor antagonists.
Wolf H
Scand J Rheumatol Suppl; 2000; 113():37-45. PubMed ID: 11028830
[TBL] [Abstract][Full Text] [Related]
15. Irritable bowel syndrome: new agents targeting serotonin receptor subtypes.
De Ponti F; Tonini M
Drugs; 2001; 61(3):317-32. PubMed ID: 11293643
[TBL] [Abstract][Full Text] [Related]
16. Current experience with 5-HT3 receptor antagonists in fibromyalgia.
Späth M
Rheum Dis Clin North Am; 2002 May; 28(2):319-28. PubMed ID: 12122920
[TBL] [Abstract][Full Text] [Related]
17. The use of 5-HT3 receptor antagonists in various rheumatic diseases--a clue to the mechanism of action of these agents in fibromyalgia?
Stratz T; Müller W
Scand J Rheumatol Suppl; 2000; 113():66-71. PubMed ID: 11028836
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
